Genetic-Metabolic News
One of the primary aims of the genetic counselor is the reduction in the number of children
born with either lethal disorders or severe CNS
dysfunction (eg. mongolism and midline neural defects). Generally, this goal is accomplished in one
of four major ways:
1) Where a child's disorder is known to be
inherited in a Mendelian fashion, by clearly
stating the recurrence risk of 1 : 2 or 1 : 4,
which is often a deterrent to a parent pair
to plan further pregnancies;
2) By counseling based on empirically established recurrence risk statistics;
3) Where the risk is high, by determining the
status of the fetus at 14-16 weeks by
aspiration and study of amniotic fluid (amniocentesis,)-when the mother is over
age 40, or has had a previous child with
mongolism, a sex-linked disorder, or one of
so~ fifty metabolic disorders which may
be diagnosed by amniotic fluid study, the
pregnancy can be terminated before twenty
weeks gestation if one of the disorders is
detected;
4) By ascertainment of parent pairs where
both are carriers of an autosomal recessive
disorder before birth of an involved child
so that parents may be advised of the high
risk of occurrence of this disorder in their
offspring and also be advised of the availability or nonavailability of intrauterine
diagnosis by amniocentesis.
At present, two carrier detection programs (for
sickle cell anemia and Tay-Sachs disease) have been
developed because the following necessary criteria
have been met:
1) The carrier test is rapid, accurate, and inexpensive within a defined population;
2) The frequency of the carrier state is high
enough within a defined population to justify the
cost of testing;
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3) The disorder is a serious health hazard for
which there is no definitive cure.
One other disorder, cystic fibrosis (rare in the
Black race) meets criteria 2 and 3 but unfortunately,
not 1. As soon as an effective carrier test for this
disease is developed, however, it will be offered
to whites just as today, blacks have available sickle
cell testing and Jews, a Tay-Sachs screening test.
The major purpose of this article is to briefly
summarize the concept of a Tay-Sachs carrier detection program and to share our experiences in
Virginia. This disease, first described by Drs. Tay
and Sachs in the 1880's, was classified for over
sixty years as a "degenerative disorder" of the
central nervous system (CNS).
Approximately five years ago, however, it was
shown that the disorder is due to the deficient
activity of an enzyme, hexosaminidase A, which
catabolizes a normally occurring ganglioside. The
accumulation of this sphingolipid causes progressive
CNS deterioration in an infant who previously developed normally for the first six-to-nine months
of life. Death by the age of four or five is inevitable
since no cure is available or imminent.
Over the past few years, an accurate procedure
for the quantitation of hexosaminidase A (hex A)
activity in serum has been developed whioh identifies
the carriers of this autosomal recessive disorder.
Because the Tay-Sachs disease occurs one hundred
times as frequently in Ashkenazi Jews (those Jews
of Eastern European and Russian ancestry who
represent 90% of the United States Jews) as compared to Gentiles and Sephardic Jews, it has become
feasible and advisable to use this test to screen this
population for the carrier state. Identification of
the carrier is important for the following reasons:
1) It alerts relatives of carriers (through appropriate genetic counseling) of their very
high- risk for also being a carrier;
2) It allows identification of couples in the
childbearing age who may both have the
abnormal gene and are therefore at a 1 : 4
43

GENETIC-METABOLIC NEWS

44

risk for having a Tay-Sachs infant. If both
members of a parent pair are carriers,
three alternatives exist:
a) limitation of family size;
b) therapeutic termination of an involved fetus
diagnosed by amniocentesis in the 4th
month of pregnancy;
c) artificial insemination from a male known
not to be a Tay-Sachs carrier-this approach would only be suggested where
amniocentesis or termination of pregnancy
are not acceptable to the parents.
Over the past twenty months, the Departments
of Pediatrics and Pathology at MCV, in cooperation
with the Virginia State Health Department and
concerned local physicians and volunteers, have
organized intensive educational campaigns to outline the rationale of Tay-Sachs carrier testing. These
efforts in Richmond, Roanoke, Norfolk-Virginia
Beach, Hampton-Newport News, and Fredericksburg, have yielded a voluntary turnout of over 3600
adult Jews at designated testing dates in community
centers.
Complete analysis of over 2000 specimens
has thus far disclosed a carrier incidence of 1: 30.
This figure is in close agreement with the 1 : 28
figure found by the first and largest "outreach"
Tay-Sachs screening program-that developed by
Dr. Michael Kaback of the Johns Hopkins University Medical Center for the Baltimore-Washington area. Approximately a dozen other large
cities have launched similar programs, but none
has surpassed the Virginia experience in providing
this testing to so many people over so large an area.
Of equal importance to education and testing
in such a detection program is the availability of
adequate counseling for the carrier. Professional
genetic counselors have provided this service for
every Tay-Sachs carrier in Virginia, including advice
concerning the importance and method of testing
at-risk relatives.
The ultimate national goal of such a carrier
detection program is to avert the birth of TaySachs children. This could be done most efficiently
by testing only married Jewish couples in the
child-bearing age prior to their planning any children. Because lack of funds and the complexity of
the enzyme measurement presently prohibit the
wide spread availability of the test, however, this
is not feasible in most areas of the country. Logic
dictates, therefore, that the best alternative is first

to identify which families (in cities where the test
is available) carry the gene abnormality and then
to urge testing for high-risk relatives residing in
smaller cities where screening is not available. The
MCV Tay-Sachs Screening Program has received
frozen serum from as distant a city as Niagara
Falls, New York, where the relative of a Richmond
carrier resided.
For further information regarding the MCV
Tay-Sachs Screening Program, contact either Dr.
Peter Mamunes or Dr. Seymour Bakerman by
writing to Box 187, Medical College of Virginia,
Richmond 23298, or by telephoning 804-770-3033.
Sickle cell disease differs from Tay-Sachs disease in many ways. From the standpoint of carrier
detection programs, however, the most important
differences are that:
1) The test is much simpler and blood specimens can be mailed into a central laboratory;
2) The carrier rate is considerably higherapproximately 1: 12;
3) No prenatal test is available when both
parents are known carriers.
For these reasons, a greater effort of education and
testing at an earlier age are indicated.
Much of the screening for sickle cell trait in
in the state of Virginia is accomplished by the
Virginia Sickle Cell Anemia Awareness Program
(VaSCAP) of the Medical College of Virginia, and
the sickle cell program of the State Health Department. The purposes of these programs are to educate the public, to provide a screening for young
people who wish to know whether they carry the
recessive trait for sickling, and to provide counseling
for those who have been tested.
The VaSCAP program at the Medical College
of Virginia tests young people in the child-bearing
age, as well as premarital blood samples when
the test is desired. A total of 11,000 specimens
per year have been screened, many of them from
the Richmond metropolitan area. The laboratory
of the Stat0 Health Department has a capacity for
up to 40,000 tests a year and collects samples from
all over the state from individuals of any age.
The VaSCAP program at MCV also provides
educational services for the school systems in greater
Richmond and other outlying areas, as well as educational programs for organizations and health
clinics where it is requested. Screening programs
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are provided for public schools and colleges in the
area, and counseling programs are offered for individuals tested in the program. In addition, the
VaSCAP program has provided a series of seminars
for public health nurses throughout the state to
teach a larger number of individuals the principles
of counseling for sickle cell trait.
The offices of the Virginia Sickle Cell Anemia
Awareness Program are at 1008 East Clay Street,
Richmond, Virginia 23298, and the program is
supervised by Mrs. Florence Cooper. The telephone
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number is 770-7797. The program of the State
Health Department is directed by Dr. Patricia Hunt,
Director, Bureau of Child Health, with offices in
the Madison Building in Richmond.
Carrier detection programs, such as those above
described, have proven that the public will voluntarily present themselves for testing if there is appropriate precedent education and follow-up counseling. Every physician should acquaint himself with
these recently available services and join the effort
to reduce the incidence of these dreadful disorders.

